Copyright
©The Author(s) 2003.
World J Gastroenterol. Dec 15, 2003; 9(12): 2695-2697
Published online Dec 15, 2003. doi: 10.3748/wjg.v9.i12.2695
Published online Dec 15, 2003. doi: 10.3748/wjg.v9.i12.2695
Table 1 Clinical characteristics of patients on anti-viral treat-ments and controls
| Overall (n = 131) | Controls (n = 96) | Lamivudine (n = 35) | P value | |
| Age | 30 (12-68) | 29 (12-68) | 38 (22-47) | 0.007 |
| Male gender (n,%) | 75 (57%) | 50 (52%) | 25 (71%) | 0.074 |
| Initial ALT (IU/l) | 73 (17-1122) | 57.5 (17-753) | 135 (36-1122) | < 0.001 |
| Follow-up (months) | 39 (18-49) | 39 (19-49) | 27 (18-46) | 0.009 |
| Genotype | 0.40 | |||
| B (n,%) | 43 (33%) | 29 (30%) | 14 (40%) | |
| C (n,%) | 88 (67%) | 67 (70%) | 21 (60%) | |
| HBeAg | 28 (21%) | 24 (25%) | 4 (11%) | 0.15 |
| seroconversion (n,%) |
- Citation: Chan HLY, Wong ML, Hui AY, Chim AML, Tse AML, Hung LCT, Chan FKL, Sung JJY. Hepatitis B virus genotype has no impact on hepatitis B e antigen seroconversion after lamivudine treatment. World J Gastroenterol 2003; 9(12): 2695-2697
- URL: https://www.wjgnet.com/1007-9327/full/v9/i12/2695.htm
- DOI: https://dx.doi.org/10.3748/wjg.v9.i12.2695